Print

ANRS VAC 01

A randomised trial to compare the tolerance and immunogenicity of a ?candidate vaccine protocol for HIV-1, ALVAC-vCP125 and rgp160 boost provided in two different adjuvants in HIV negative adult volunteers

Trial Details:

I Completed
French National Agency for Research on AIDS and viral hepatitis (ANRS) June 01, 1992
ALVAC vCP125,gp160 Vaccine (Immuno-AG) Canarypox Env gp160 B MN; Protein gp160 env B LAI, MN
ALVAC vCP125 Viral Vector - Pox
gp160 Vaccine (Immuno-AG) Protein
France 20
http://www.anrs.fr/